National trends for axillary lymph node dissection and survival outcomes for clinical T3/T4 node-negative breast cancer patients undergoing mastectomy with positive lymph nodes.

Szczegóły
Abstrakt

Tytuł:: National trends for axillary lymph node dissection and survival outcomes for clinical T3/T4 node-negative breast cancer patients undergoing mastectomy with positive lymph nodes.
Autorzy:: Reyna C; Division of Breast Surgery, Department of Surgery, Crozer Health System, 2100 Keystone Ave, MOB 1st Floor, Drexel Hill, PA, USA. .; Section of Surgical Oncology, Department of Surgery, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Suite 1466, Cincinnati, OH, 45267, USA. .
Johnston ME; Cincinnati Research On Outcomes and Safety in Surgery (CROSS), Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Morris MC; Cincinnati Research On Outcomes and Safety in Surgery (CROSS), Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Lee TC; Cincinnati Research On Outcomes and Safety in Surgery (CROSS), Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Hanseman D; Division of Research-Biostatics, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Shaughnessy EA; Division of Surgical Oncology, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Lewis JD; Division of Surgical Oncology, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Źródło:: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Aug; Vol. 189 (1), pp. 155-166. Date of Electronic Publication: 2021 Jun 18.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Dordrecht : Kluwer Academic
Original Publication: The Hague ; Boston : M. Nijhoff, c1981-
MeSH Terms:: Breast Neoplasms*/epidemiology
Breast Neoplasms*/surgery
Sentinel Lymph Node*
Axilla ; Female ; Humans ; Lymph Node Excision ; Lymph Nodes/surgery ; Mastectomy ; Sentinel Lymph Node Biopsy
References:: Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318(10):918–926. (PMID: 10.1001/jama.2017.11470)
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575. (PMID: 10.1001/jama.2011.90)
Chung A, Gangi A, Mirocha J, Giuliano A (2015) Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery. Ann Surg Oncol 22:1128–1132. (PMID: 10.1245/s10434-014-4090-y)
Bonneau C, Hequet D, Estevez JP, Pouget N, Rouzier R (2015) Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes. Eur J Surg Oncol 41(8):998–1004. (PMID: 10.1016/j.ejso.2015.04.003)
Snow R, Reyna C, Johns C, Lee MC, Sun W, Fulp WJ et al (2015) Outcomes with and without axillary node dissection for node-positive lumpectomy and mastectomy patients. Am J Surg 210(4):685–693. (PMID: 10.1016/j.amjsurg.2015.05.004)
Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J et al (2012) Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol 19(12):3762–3770. (PMID: 10.1245/s10434-012-2386-3)
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305. (PMID: 10.1016/S1470-2045(13)70035-4)
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310. (PMID: 10.1016/S1470-2045(14)70460-7)
Park TS, Thomas SM, Rosenberger LH, Fayanju OM, Plichta JK, Blitzblau RC et al (2018) The association of extent of axillary surgery and survival in women with N2–3 invasive breast cancer. Ann Surg Oncol 25(10):3019–3029. (PMID: 10.1245/s10434-018-6587-2)
Ong CT, Thomas SM, Blitzblau RC, Fayanju OM, Park TS, Plichta JK et al (2017) Patient age and tumor subtype predict the extent of axillary surgery among breast cancer patients eligible for the American college of surgeons oncology group trial Z0011. Ann Surg Oncol 24(12):3559–3566. (PMID: 10.1245/s10434-017-6075-0)
Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27(18):2946–2953. (PMID: 10.1200/JCO.2008.19.5750)
Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF et al (2010) Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. J Ann Surg Oncol 17(Suppl 3):343–351. (PMID: 10.1245/s10434-010-1253-3)
Yao K, Liederbach E, Pesce C, Wang CH, Winchester DJ (2015) Impact of the American college of surgeons oncology group Z0011 randomized trial on the number of axillary nodes removed for patients with early-stage Breast cancer. J Am Coll Surg 221(1):71–81. (PMID: 10.1016/j.jamcollsurg.2015.02.035)
Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y et al (2019) Evolution in practice patterns of axillary management following mastectomy in patients with 1–2 positive sentinel nodes. Breast Cancer Res Treat 176(2):435–444. (PMID: 10.1007/s10549-019-05243-7)
Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC (2018) Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol 25(8):2241–2248. (PMID: 10.1245/s10434-018-6531-5)
FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK et al (2017) Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. Ann Surg Oncol 24(3):652–659. (PMID: 10.1245/s10434-016-5605-5)
Fu Y, Chung D, Cao M-A, Apple S, Chang H (2014) Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer? Ann Surg Oncol 21(13):4109–4123. (PMID: 10.1245/s10434-014-3814-3)
García-Novoa A, Acea-Nebril B, Casal-Beloy I, Bouzón-Alejandro A, Cereijo Garea C, Gómez-Dovigo A et al (2019) The decline of axillary lymph node dissection in breast cancer. Evolution of its indication over the last 20 years. Cir Esp 97(4):222–9. (PMID: 10.1016/j.ciresp.2019.01.010)
Yadav BS, Sharma SC, Singh R, Singh G, Kumar V (2007) Postmastectomy radiation and survival in patients with breast cancer. J Cancer Res Ther 3(4):218–224. (PMID: 10.4103/0973-1482.38997)
Almahariq MF, Quinn TJ, Siddiqui ZA, Thompson AB, Jawad MS, Chen PY et al (2020) Post-mastectomy radiotherapy is associated with improved overall survival in T3N0 patients who do not receive chemotherapy. Radiother Oncol 145:229–237. (PMID: 10.1016/j.radonc.2020.01.022)
Early Breast Cancer Trialists Collaborative Group, McGale P, Taylor C, Correa C, Cutter D, Duane F et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–35. (PMID: 10.1016/S0140-6736(14)60488-8)
Mathias BJ, Sun J, Sun W, Zhou J-M, Fulp WJ, Laronga C et al (2020) Surgeon bias in the management of positive sentinel lymph nodes. Clin Breast Cancer. https://doi.org/10.1016/j.clbc.2020.07.010. (PMID: 10.1016/j.clbc.2020.07.01032917535)
Sun J, Mathias BJ, Laronga C, Sun W, Zhou J-M, Fulp WJ et al (2021) Impact of axillary dissection among patients with sentinel node-positive breast cancer undergoing mastectomy. J Natl Compr Canc Netw 19(1):40. (PMID: 10.6004/jnccn.2020.7597)
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933. (PMID: 10.1016/S1470-2045(10)70207-2)
Contributed Indexing:: Keywords: Axillary lymph node dissection; Breast cancer; Breast conserving therapy
Entry Date(s):: Date Created: 20210618 Date Completed: 20210727 Latest Revision: 20210727
Update Code:: 20240104
DOI:: 10.1007/s10549-021-06290-9
PMID:: 34143359
: Czasopismo naukowe

Full Text Finder

Purpose: Previous studies have suggested axillary lymph node dissection (ALND) can be omitted in early breast cancer patients undergoing mastectomy with positive lymph nodes (LNs). We assessed the national utilization of ALND and overall survival (OS) for larger, locally advanced tumors in patients undergoing mastectomy with positive LNs.
Methods: The National Cancer Database from 2006 to 2016 was queried for mastectomy patients with clinical T3/T4, N0 tumors, and 1-2 positive LNs. Trends and outcomes for ALND were compared to sentinel lymph node biopsy (SLNB) alone.
Results: Thousand nine hundred and seventeen women were included. The proportion of ALND decreased from 70% pre-Z0011 to 52% post-Z0011. On Kaplan-Meier analysis, ALND had better OS compared to SLNB alone (p < 0.01). On multivariate analysis, age (p < 0.01), chemotherapy (p < 0.01), and hormonal therapy (p < 0.01) were associated with better OS. In patients who received adjuvant radiation therapy (ART) ALND improved OS on multivariate analysis (p < 0.01).
Conclusion: This is the first large database study to demonstrate a national trend to forego ALND in mastectomy patients with large or locally advanced tumors (T3/T4abc) and 1-2 positive lymph nodes. This study suggests a survival benefit for ALND, particularly in patients receiving ART. Careful consideration and further investigations should be performed prior to omitting ALND this patient population.
(© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Informacja